Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.

Our vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please visit the Oxford COVID-19 vaccine web hub or visit the COVID-19 trial website. 

The first such large scale centre to be set up by Oxford Health NHS Foundation Trust, the Kassam Stadium, home to the city’s League One football side, will be open to the public by invite-only, seven days a week, from 8am to 8pm, as part of the national effort to vaccinate against COVID-19.  

Prof. Pollard said:  

‘To see a vaccination centre in Oxford delivering the vaccine that was developed in the city is a great moment. So much hard work has gone into getting to this stage from the researchers developing the vaccine and the Oxford Health team making all the arrangements to set up and run an efficient vaccination centre. Many volunteers from Oxfordshire took part in the clinical trials and it is a huge credit to their commitment that we can benefit from this vaccine today. 

‘We anticipate that the vaccination of as many people as possible as soon as possible will start to have a big impact on hospitalisations and is something everyone has been hoping for. However, vaccination is only one part of the story - people should continue to follow public health measures, such as observing the rules of lockdown, social distancing, wearing masks and washing their hands until we get the virus back under control.’  

The new vaccination centre will kick off by vaccinating priority front line patient-facing staff who work on community and mental health wards as well as in the community via services like district nursing, before opening its doors to patients.  

People aged 75 and over will shortly be invited via the national booking system to make an appointment for their first vaccination of the Oxford AstraZeneca vaccine at the Kassam. If they cannot or do not want to travel to a vaccination centre people can wait to be invited to be immunised by a local GP service or hospital hub.  

People are reminded not to turn up to the Kassam Stadium without an appointment. 

Similar stories

Oxford University extends COVID-19 vaccine study to children

COVID-19 Research

The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.

World Health Organization experts provide guidance on use of the Oxford vaccine

COVID-19 Research

WHO SAGE says Oxford's coronavirus vaccine is safe and likely to be efficacious in older adults, and recommends its use in this age group.

Oxford leads first trial investigating dosing with alternating vaccines

COVID-19 Research

The Oxford Vaccine Group is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.

Oxford vaccine researchers talk research and home-schooling on ITV's This Morning

COVID-19 Public Engagement

Professor Katie Ewer (The Jenner Institute) and Dr Maheshi Ramasamy (Oxford Vaccine Group) appeared on ITV's This Morning on Wednesday 6 January to talk about their work developing the ChAdOx1 nCoV-19 coronavirus vaccine, all while juggling the demands of young families and home-schooling.

Oxford vaccine stimulates broad antibody and T cell functions

COVID-19 Publication Research

Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.